Regeneron, Roche's antibody cocktail cuts COVID-19 hospitalizations, deaths by 70%, company says
Fox News
A combination monoclonal antibody cocktail produced by Regeneron and Roche has shown to reduce hospitalization or death in COVID-19 patients by as much as 70%, a press release posted Tuesday said.
The currently authorized dosage is 1,200 mg of casirivimab and 1,200 mg of imdevimab administered together as a single infusion within 10 days of symptom onset. The press release, published by Regeneron Pharmaceuticals, Inc., also noted that the therapy reduced symptom duration and that a companion Phase 2 trial saw reduced viral load reductions in patients given low doses of REGEN-COV. The trial saw patients given 300 mg intravenously and 600 mg subcutaneously, with researchers noting reductions over the first seven days comparable to those given the 2,400 mg and 1,200 mg intravenous doses.More Related News